Radiofrequency ablation as a novel therapy for pulmonary metastasis from colorectal cancer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Radiofrequency (RF) ablation is a thermal therapy that results in coagulation necrosis. Initially, RF ablation was mainly used for treating hepatocellular carcinoma. Favorable outcomes in the treatment of hepatocellular carcinoma have encouraged the application of this technique to neoplasms in other organs, including the lungs. RF ablation for lung cancer may be carried out percutaneously by using computed tomographic (CT) guidance; the techniques used in this therapy are simple and quite similar to those used in CT-guided lung biopsy. Mortality rate has been reported to be 0.4%. There have been promising survival data after RF ablation: 68% at 2 years, 74% at 3 years, and 75% at 2 years for patients with clinical stage I non-small-cell lung cancer; and 66% at 2 years and 46%-48% at 3 years for patients with metastatic colorectal cancer. Therefore, RF ablation of lung cancer is currently one of the hot topics in interventional radiology. In this commentary, we describe the outcomes of RF ablation as a novel therapy for pulmonary metastasis from colorectal cancer.

Original languageEnglish
Title of host publicationColorectal Cancer: Risk, Diagnosis and Treatments
PublisherNova Science Publishers, Inc.
Pages203-208
Number of pages6
ISBN (Print)9781617613012
Publication statusPublished - Jan 2011

Fingerprint

Ablation
Colorectal Neoplasms
Neoplasm Metastasis
Lung
Hepatocellular Carcinoma
Lung Neoplasms
Interventional Radiology
Non-Small Cell Lung Carcinoma
Necrosis
Therapeutics
Hot Temperature
Biopsy
Radiology
Survival
Mortality
Coagulation
Neoplasms
Cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Hiraki, T., Gobara, H., Mimura, H., & Kanazawa, S. (2011). Radiofrequency ablation as a novel therapy for pulmonary metastasis from colorectal cancer. In Colorectal Cancer: Risk, Diagnosis and Treatments (pp. 203-208). Nova Science Publishers, Inc..

Radiofrequency ablation as a novel therapy for pulmonary metastasis from colorectal cancer. / Hiraki, Takao; Gobara, Hideo; Mimura, Hidefumi; Kanazawa, Susumu.

Colorectal Cancer: Risk, Diagnosis and Treatments. Nova Science Publishers, Inc., 2011. p. 203-208.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hiraki, T, Gobara, H, Mimura, H & Kanazawa, S 2011, Radiofrequency ablation as a novel therapy for pulmonary metastasis from colorectal cancer. in Colorectal Cancer: Risk, Diagnosis and Treatments. Nova Science Publishers, Inc., pp. 203-208.
Hiraki T, Gobara H, Mimura H, Kanazawa S. Radiofrequency ablation as a novel therapy for pulmonary metastasis from colorectal cancer. In Colorectal Cancer: Risk, Diagnosis and Treatments. Nova Science Publishers, Inc. 2011. p. 203-208
Hiraki, Takao ; Gobara, Hideo ; Mimura, Hidefumi ; Kanazawa, Susumu. / Radiofrequency ablation as a novel therapy for pulmonary metastasis from colorectal cancer. Colorectal Cancer: Risk, Diagnosis and Treatments. Nova Science Publishers, Inc., 2011. pp. 203-208
@inbook{0f21878b267242079985d605b26a6584,
title = "Radiofrequency ablation as a novel therapy for pulmonary metastasis from colorectal cancer",
abstract = "Radiofrequency (RF) ablation is a thermal therapy that results in coagulation necrosis. Initially, RF ablation was mainly used for treating hepatocellular carcinoma. Favorable outcomes in the treatment of hepatocellular carcinoma have encouraged the application of this technique to neoplasms in other organs, including the lungs. RF ablation for lung cancer may be carried out percutaneously by using computed tomographic (CT) guidance; the techniques used in this therapy are simple and quite similar to those used in CT-guided lung biopsy. Mortality rate has been reported to be 0.4{\%}. There have been promising survival data after RF ablation: 68{\%} at 2 years, 74{\%} at 3 years, and 75{\%} at 2 years for patients with clinical stage I non-small-cell lung cancer; and 66{\%} at 2 years and 46{\%}-48{\%} at 3 years for patients with metastatic colorectal cancer. Therefore, RF ablation of lung cancer is currently one of the hot topics in interventional radiology. In this commentary, we describe the outcomes of RF ablation as a novel therapy for pulmonary metastasis from colorectal cancer.",
author = "Takao Hiraki and Hideo Gobara and Hidefumi Mimura and Susumu Kanazawa",
year = "2011",
month = "1",
language = "English",
isbn = "9781617613012",
pages = "203--208",
booktitle = "Colorectal Cancer: Risk, Diagnosis and Treatments",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Radiofrequency ablation as a novel therapy for pulmonary metastasis from colorectal cancer

AU - Hiraki, Takao

AU - Gobara, Hideo

AU - Mimura, Hidefumi

AU - Kanazawa, Susumu

PY - 2011/1

Y1 - 2011/1

N2 - Radiofrequency (RF) ablation is a thermal therapy that results in coagulation necrosis. Initially, RF ablation was mainly used for treating hepatocellular carcinoma. Favorable outcomes in the treatment of hepatocellular carcinoma have encouraged the application of this technique to neoplasms in other organs, including the lungs. RF ablation for lung cancer may be carried out percutaneously by using computed tomographic (CT) guidance; the techniques used in this therapy are simple and quite similar to those used in CT-guided lung biopsy. Mortality rate has been reported to be 0.4%. There have been promising survival data after RF ablation: 68% at 2 years, 74% at 3 years, and 75% at 2 years for patients with clinical stage I non-small-cell lung cancer; and 66% at 2 years and 46%-48% at 3 years for patients with metastatic colorectal cancer. Therefore, RF ablation of lung cancer is currently one of the hot topics in interventional radiology. In this commentary, we describe the outcomes of RF ablation as a novel therapy for pulmonary metastasis from colorectal cancer.

AB - Radiofrequency (RF) ablation is a thermal therapy that results in coagulation necrosis. Initially, RF ablation was mainly used for treating hepatocellular carcinoma. Favorable outcomes in the treatment of hepatocellular carcinoma have encouraged the application of this technique to neoplasms in other organs, including the lungs. RF ablation for lung cancer may be carried out percutaneously by using computed tomographic (CT) guidance; the techniques used in this therapy are simple and quite similar to those used in CT-guided lung biopsy. Mortality rate has been reported to be 0.4%. There have been promising survival data after RF ablation: 68% at 2 years, 74% at 3 years, and 75% at 2 years for patients with clinical stage I non-small-cell lung cancer; and 66% at 2 years and 46%-48% at 3 years for patients with metastatic colorectal cancer. Therefore, RF ablation of lung cancer is currently one of the hot topics in interventional radiology. In this commentary, we describe the outcomes of RF ablation as a novel therapy for pulmonary metastasis from colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=84892026635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892026635&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84892026635

SN - 9781617613012

SP - 203

EP - 208

BT - Colorectal Cancer: Risk, Diagnosis and Treatments

PB - Nova Science Publishers, Inc.

ER -